| May 10 |
UroGen Pharma Q1 2024 Earnings Preview
|
| May 5 |
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
|
| May 4 |
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
|
| May 4 |
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
|
| May 3 |
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
|
| Apr 22 |
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
|
| Apr 17 |
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
|
| Apr 15 |
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
| Apr 14 |
UroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week
|
| Apr 3 |
Urogen files patent suit against Teva over cancer therapy
|
